JNJ vs. MEDP: Johnson & Johnson vs. Medpace Stock Comparison

November 11, 2026

How do Johnson & Johnson (JNJ) and Medpace (MEDP) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Johnson & Johnson (JNJ) and Medpace (MEDP) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JNJ is classified in Pharmaceuticals while MEDP is classified in Life Sciences Tools & Services.

Company profile comparison for Johnson & Johnson (JNJ) and Medpace (MEDP)
Profile Item	JNJ	MEDP
Name	Johnson & Johnson	Medpace Holdings, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Life Sciences Tools & Services
GICS Sub-Industry	Pharmaceuticals	Life Sciences Tools & Services
Market Capitalization	664.95 billion USD	18.27 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	January 2, 1962	August 11, 2016
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

JNJ

MEDP

GSPC

Johnson & Johnson (JNJ) vs. Medpace (MEDP), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Johnson & Johnson (JNJ) and Medpace (MEDP). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Johnson & Johnson (JNJ) and Medpace (MEDP). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Johnson & Johnson (JNJ) and Medpace (MEDP)
Metric	JNJ	MEDP
Total Return (1Y)	53.82%	13.29%
Total Return (3Y, Annualized)	27.51%	35.26%
Total Return (5Y, Annualized)	14.71%	24.49%

Risk Profile

Drawdown History

JNJ

MEDP

GSPC

Johnson & Johnson (JNJ) vs. Medpace (MEDP), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Johnson & Johnson (JNJ) and Medpace (MEDP). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Johnson & Johnson (JNJ) and Medpace (MEDP)
Metric	JNJ	MEDP
Volatility (1Y, Annualized)	21.23%	44.16%
Beta (5Y)	0.21	1.10
Max Drawdown (5Y)	-18.41%	-42.87%
Avg. Volume (3M)	6.93M	258.39K

Risk-Adjusted Performance

Risk-Return Positioning

JNJ and MEDP are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Johnson & Johnson (JNJ) and Medpace (MEDP)
Metric	JNJ	MEDP
Sharpe Ratio (1Y)	2.33	0.20
Sortino Ratio (1Y)	3.66	0.26

Profitability

ROE (TTM)

Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; Johnson & Johnson (JNJ) at 20.02% also sits in the top quartile.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max: 109.18%
JNJ: 20.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP: 117.88%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Medpace (MEDP) at 18.24% keeps the most of each sales dollar — above its industry’s net margin range — and Johnson & Johnson (JNJ) at 16.20% also retains a top-quartile share.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.20%

Max: 18.05%
JNJ: 16.20%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP: 18.24%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Johnson & Johnson (JNJ) at 25.74% and Medpace (MEDP) at 23.12% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.74%

Max: 83.12%
JNJ: 25.74%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max: 83.12%
MEDP: 23.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Johnson & Johnson (JNJ) and Medpace (MEDP)
Metric	JNJ	MEDP
ROE (TTM)	20.02%	117.88%
ROA (TTM)	8.46%	18.71%
Net Margin (TTM)	16.20%	18.24%
Operating Margin (TTM)	25.74%	23.12%
Gross Margin (TTM)	67.78%	72.24%

Growth

Revenue Growth

Both Johnson & Johnson (JNJ) at 6.05% and Medpace (MEDP) at 19.97% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their Revenue Growth across different time periods.

EPS Growth

Johnson & Johnson (JNJ) at 90.50% sits in the top EPS growth quartile, while Medpace (MEDP) at 20.98% is closer to the peer norm — faster per-share earnings growth for JNJ.

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Johnson & Johnson (JNJ) and Medpace (MEDP)
Metric	JNJ	MEDP
Revenue Growth (YoY)	6.05%	19.97%
Revenue Growth (3Y CAGR)	5.60%	20.12%
EPS Growth (YoY)	90.50%	20.98%
EPS Growth (3Y CAGR)	17.90%	28.04%

Financial Strength

Current Ratio (MRQ)

Both Johnson & Johnson (JNJ) at 1.02 and Medpace (MEDP) at 0.83 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.02

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
JNJ: 1.02
Min: 0.10

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MEDP: 0.83
Min: 0.10

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Johnson & Johnson (JNJ) at 0.55 and Medpace (MEDP) at 0.29 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.55

Max: 1.42
Q3: 0.65
JNJ: 0.55
Median: 0.15
Q1: 0.02
Min: 0.00

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max: 1.42
Q3: 0.65
MEDP: 0.29
Median: 0.15
Q1: 0.02
Min: 0.00

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Johnson & Johnson (JNJ) and Medpace (MEDP)
Metric	JNJ	MEDP
Current Ratio (MRQ)	1.02	0.83
Debt / Equity (MRQ)	0.55	0.29
Net Debt / EBITDA	0.79	-0.84

Dividends

Dividend Yield (TTM)

Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

JNJ: 1.94%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Medpace (MEDP) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

80.12%

JNJ: 80.12%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Johnson & Johnson (JNJ) and Medpace (MEDP)
Metric	JNJ	MEDP
Dividend Yield (TTM)	1.94%	0.00%
Dividend Payout Ratio (TTM)	80.12%	0.00%

Valuation

P/E Ratio (TTM)

Both Johnson & Johnson (JNJ) at 41.92 and Medpace (MEDP) at 36.26 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.92

Max: 85.34
Q3: 43.46
JNJ: 41.92
Median: 26.69
Q1: 13.30
Min: 0.07

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max: 85.34
Q3: 43.46
MEDP: 36.26
Median: 26.69
Q1: 13.30
Min: 0.07

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Johnson & Johnson (JNJ) at 6.69 and Medpace (MEDP) at 6.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 58.18
Q3: 25.77
Median: 7.30
JNJ: 6.69
Q1: 3.01
Min: 0.01

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max: 58.18
Q3: 25.77
Median: 7.30
MEDP: 6.44
Q1: 3.01
Min: 0.01

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Johnson & Johnson (JNJ) at 8.16 sits in the upper P/B ratio quartile, and Medpace (MEDP) at 31.23 prices even higher, above its industry range.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 13.53
JNJ: 8.16
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP: 31.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Johnson & Johnson (JNJ) vs. Medpace (MEDP): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Johnson & Johnson (JNJ) and Medpace (MEDP)
Metric	JNJ	MEDP
P/E Ratio (TTM)	41.92	36.26
P/S Ratio (TTM)	6.69	6.44
P/B Ratio (MRQ)	8.16	31.23
Free Cash Flow Yield (TTM)	2.78%	2.72%